[HTML][HTML] The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort …
C Zhou, Z Wang, C Fu, H Tao, C Liu - Annals of Translational …, 2023 - ncbi.nlm.nih.gov
Background Acquired drug resistance to various tyrosine kinase inhibitor (TKI) inevitably
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study
C Zhou, Z Wang, C Fu, H Tao… - Annals of translational …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Acquired drug resistance to various tyrosine kinase inhibitor (TKI) inevitably
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
[HTML][HTML] The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort …
C Zhou, Z Wang, C Fu, H Tao… - Annals of Translational …, 2023 - atm.amegroups.org
Background: Acquired drug resistance to various tyrosine kinase inhibitor (TKI) inevitably
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study
C Zhou, Z Wang, C Fu, H Tao, C Liu - Annals of Translational …, 2023 - europepmc.org
Background Acquired drug resistance to various tyrosine kinase inhibitor (TKI) inevitably
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
[PDF][PDF] The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort …
C Zhou, Z Wang, C Fu, H Tao, C Liu - 2023 - cdn.amegroups.cn
Background: Acquired drug resistance to various tyrosine kinase inhibitor (TKI) inevitably
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort study.
C Zhou, Z Wang, C Fu, H Tao, C Liu - Annals of Translational …, 2023 - europepmc.org
Background Acquired drug resistance to various tyrosine kinase inhibitor (TKI) inevitably
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
develops in almost all epidermal growth factor receptor (EGFR)-mutant non-small cell lung …
[引用][C] The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor failure: a retrospective real-world cohort …
C Zhou, Z Wang, C Fu, H Tao… - Annals of Translational …, 2023 - atm.amegroups.org
The efficacy and safety of PD-1 inhibitors for EGFR-mutant non-small cell lung cancer after
tyrosine kinase inhibitor failure: a retrospective real-world cohort study - Zhou - Annals of …
tyrosine kinase inhibitor failure: a retrospective real-world cohort study - Zhou - Annals of …